PNC Financial Services Group’s Anavex Life Sciences AVXL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $586K | Buy |
63,511
+5,838
| +10% | +$53.8K | ﹤0.01% | 1450 |
|
|
2025
Q1 | $495K | Buy |
57,673
+9,966
| +21% | +$85.5K | ﹤0.01% | 1522 |
|
|
2024
Q4 | $512K | Hold |
47,707
| – | – | ﹤0.01% | 1510 |
|
|
2024
Q3 | $271K | Buy |
47,707
+8,400
| +21% | +$47.7K | ﹤0.01% | 1967 |
|
|
2024
Q2 | $166K | Buy |
39,307
+16,353
| +71% | +$69K | ﹤0.01% | 2276 |
|
|
2024
Q1 | $117K | Buy |
22,954
+5,222
| +29% | +$26.6K | ﹤0.01% | 2519 |
|
|
2023
Q4 | $165K | Buy |
17,732
+280
| +2% | +$2.61K | ﹤0.01% | 2287 |
|
|
2023
Q3 | $114K | Sell |
17,452
-1,262
| -7% | -$8.27K | ﹤0.01% | 2489 |
|
|
2023
Q2 | $152K | Buy |
18,714
+1,262
| +7% | +$10.3K | ﹤0.01% | 2390 |
|
|
2023
Q1 | $150K | Buy |
17,452
+2,000
| +13% | +$17.1K | ﹤0.01% | 2324 |
|
|
2022
Q4 | $143K | Buy |
15,452
+2,000
| +15% | +$18.5K | ﹤0.01% | 2346 |
|
|
2022
Q3 | $139K | Buy |
13,452
+6,000
| +81% | +$62K | ﹤0.01% | 2324 |
|
|
2022
Q2 | $75K | Buy |
7,452
+4,518
| +154% | +$45.5K | ﹤0.01% | 2758 |
|
|
2022
Q1 | $36K | Buy |
2,934
+482
| +20% | +$5.91K | ﹤0.01% | 3279 |
|
|
2021
Q4 | $43K | Buy |
2,452
+452
| +23% | +$7.93K | ﹤0.01% | 3185 |
|
|
2021
Q3 | $36K | Hold |
2,000
| – | – | ﹤0.01% | 3247 |
|
|
2021
Q2 | $46K | Buy |
+2,000
| New | +$46K | ﹤0.01% | 3109 |
|
|
2017
Q1 | – | Sell |
-600
| Closed | -$2K | – | 4110 |
|
|
2016
Q4 | $2K | Buy |
+600
| New | +$2K | ﹤0.01% | 3820 |
|